Bacillus calmette-guerin substrain tice live antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Bacillus calmette-guerin substrain tice live antigen
Accession Number
DB10343
Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Attenuated
Description

Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis for percutaneous use. It is administered to prevent the development of tuberculosis.

Synonyms
  • BCG, Live, Tice Strain
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bcg VaccineInjection, powder, lyophilized, for solution50 mg/1PercutaneousOrganon USA Inc.1989-06-21Not applicableUs
OncoticePowder, for solutionIntravesicalMerck Ltd.1995-12-31Not applicableCanada
Tice BcgPowder, for suspension50 mg/50mLIntravesicalOrganon USA Inc.1990-08-24Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
2XQ558L16Z
CAS number
Not Available

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2-MethoxyethanolThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbacavirThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Abacavir.
AbataceptThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Abatacept.
AbetimusThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Abetimus.
ActeosideThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Acteoside.
AcyclovirThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Acyclovir.
AdafosbuvirThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Adafosbuvir.
AdalimumabThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Adalimumab.
AdefovirThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Adefovir.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910522
AHFS Codes
  • 80:12.00 — Vaccines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceTuberculosis Infection1
0CompletedTreatmentBladder Cancers1
1CompletedTreatmentBladder Cancers1
1CompletedTreatmentTransitional Cell Carcinoma of Bladder1
1RecruitingTreatmentRecurrent Bladder Carcinoma / Stage 0a Bladder Urothelial Carcinoma / Stage 0is Bladder Urothelial Carcinoma / Stage I Bladder Cancer1
1, 2Active Not RecruitingTreatmentBladder Cancers / High-Risk Non-Muscle-Invasive Bladder Cancer1
2, 3Not Yet RecruitingTreatmentCutaneous Metastatic Melanoma1
3Not Yet RecruitingTreatmentBladder Cancers1
3RecruitingTreatmentBladder Cancers1
3RecruitingTreatmentHigh-risk Non-muscle Invasive Bladder Cancer1
3RecruitingTreatmentStage 0 Bladder Urothelial Carcinoma / Stage 0is Bladder Urothelial Carcinoma / Stage I Bladder Urothelial Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionPercutaneous50 mg/1
Powder, for solutionIntravesical
Powder, for suspensionIntravesical50 mg/50mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:03 / Updated on November 20, 2019 07:52